Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

3.9K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.9K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.0K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.0K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.3K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.3K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

1.2K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.2K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.1K
The pathophysiology of pneumonia involves the following steps:
4.1K
Atypical Pneumonia01:14

Atypical Pneumonia

37
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
37

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020).

European respiratory review : an official journal of the European Respiratory Society·2020
Same author

Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome.

EBioMedicine·2020
Same author

Aetiological diagnosis in new adult outpatients with bronchiectasis:role of predictors derived from real life experience.

Respiratory medicine·2020
Same author

Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia.

Annals of the American Thoracic Society·2020
Same author

Systemic Inflammatory Response and Outcomes in Community-Acquired Pneumonia Patients Categorized According to the Smoking Habit or Presence of Chronic Obstructive Pulmonary Disease.

Journal of clinical medicine·2020
Same author

The importance of airway and lung microbiome in the critically ill.

Critical care (London, England)·2020
Same journal

Use of gloves: current evidence vs. current use.

Current opinion in infectious diseases·2026
Same journal

Harnessing next-generation microbial diagnostics to optimize infection management in immunocompromised hosts.

Current opinion in infectious diseases·2026
Same journal

Epidemiology, treatment and outcomes of antimicrobial-resistant infections in hematopoietic stem cell transplant recipients.

Current opinion in infectious diseases·2026
Same journal

Dengue and chikungunya vaccines past, present and future: implications for travelers.

Current opinion in infectious diseases·2026
Same journal

Oropouche virus: viral evolution, epidemiological trends, and challenges for control.

Current opinion in infectious diseases·2026
Same journal

Prevention is all you need: generative artificial intelligence for infection prevention and healthcare epidemiology.

Current opinion in infectious diseases·2026
See all related articles

Related Experiment Video

Updated: Mar 27, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.7K

Pneumococcal vaccination.

Catia Cillóniz1, Rosanel Amaro, Antoni Torres

  • 1Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, SGR 911, Ciber de Enfermedades Respiratorias (CibeRes), Barcelona, Spain.

Current Opinion in Infectious Diseases
|January 19, 2016
PubMed
Summary
This summary is machine-generated.

Pneumococcal conjugate vaccines (PCV13) significantly reduce pneumococcal diseases in children and adults. Ongoing surveillance is crucial to adapt vaccination policies and improve future prevention strategies.

More Related Videos

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.4K
Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
04:25

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

46.8K

Related Experiment Videos

Last Updated: Mar 27, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.7K
Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.4K
Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
04:25

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

46.8K

Area of Science:

  • Infectious Diseases
  • Vaccinology
  • Epidemiology

Background:

  • Pneumococcal diseases pose a significant global health burden with high morbidity and mortality.
  • Pneumococcal vaccination is essential for controlling disease spread in pediatric and adult populations.
  • Understanding disease epidemiology is key to effective prevention.

Purpose of the Study:

  • To review current knowledge on pneumococcal disease epidemiology.
  • To discuss the role and effectiveness of pneumococcal vaccines.
  • To inform current vaccination policies and future directions.

Main Methods:

  • Review of published literature on pneumococcal disease epidemiology.
  • Analysis of data on the impact of pneumococcal conjugate vaccines (PCV7, PCV13).
  • Examination of recent changes in vaccination recommendations in the US and Europe.

Main Results:

  • Pneumococcal conjugate vaccines have led to substantial decreases in disease incidence due to vaccine serotypes in vaccinated and unvaccinated individuals.
  • PCV13 demonstrated significant efficacy in adults over 65 for pneumonia and invasive pneumococcal disease.
  • Vaccination recommendations have been updated in response to vaccine impact.

Conclusions:

  • The epidemiology of pneumococcal diseases is dynamic and requires continuous monitoring.
  • Assessing the effectiveness of current vaccination policies is essential.
  • Future research should focus on optimizing strategies for pneumococcal infection prevention.